Trial Profile
A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms CARES 310
- Sponsors Jiangsu Hengrui Medicine Co.
- 05 Feb 2024 Status changed from active, no longer recruiting to completed.
- 20 Jan 2024 Results assessing patient-reported outcomes less than 65 or greater and equal to 65 years old from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma presented at the 2024 Gastrointestinal Cancers Symposium.
- 20 Jan 2024 Results of post-hoc analysis assessing impact of baseline albumin-bilirubin (ALBI) grade and Child-Pugh (CP) class on survival outcomes, presented at the 2024 Gastrointestinal Cancers Symposium.